The health insurance companies involved pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with section 130a (8) SGB V on the active substance adalimumab. The contract is concluded within the framework of the open-house biologics procedure of the health insurances:

Individual negotiations on contract contents are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity for individual contract partners. The contract period is a maximum of 24 months starting from 1.8.2019. The contract ends not later than 31.7.2021, regardless of the date of the conclusion of the contract. All further information can be found in the participation and contract documents.

Joining this open house biologics procedure is possible at any time during the contract period.

A contract is concluded with all pharmaceutical companies that fulfill the requirements of Annex 4 to the contract (self-declaration for approval and the company) and confirm this by signing it.

This notice does not concern the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or antitrust law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure "Open procedure" used in this announcement text according to section IV.1.1) and the award criteria according to section II.2.5) are due to the requirements of the announcement form and are of no further significance, hereby and with the use of the medium "TED "is no subordination under procurement regulations connected, the validity of which is not mandatory by law or regulations.